Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATT: Lucentis vs Avastin for AMD
NCT00593450Phase 3Completed
- Sponsor
- University of Pennsylvania
- Start
- Feb 2008
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in neovascular age-related macular degeneration (NVAMD), sponsored by University of Pennsylvania. Started Feb 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00593450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00593450.